Starpax Biopharma Inc.
OperatingBiotech · Montreal
Financials
FY2021–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Sep 19, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Shares | 75,500,000 | — | 100.0% | $6.25Feb 2023 |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Pierre Dozois250K (0.33%) Feb 2023 → 266K Sep 2024
- Jean-François Pruneau25K (0.03%) Feb 2023 → 88K (0.12%) Aug 2023
Principal holders% as the filing states it, Sep 19, 2024
- of the Company. Thierry Pagé1.13%of company
- Pierre Dozois265,625 Common Shares0.35%of company
- Andre Monette25,000 Common Shares0.03%of company
Sold to the crowd
- Reg A+ · Feb 202337,218 Common Shares at $6.25$232.6K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 14 filings on EDGAR- Form 1-ZApr 18, 20250001960682-25-000003EDGAR
- Form 1-UMar 12, 20250001960682-25-000002EDGAR
- Form 1-UJan 10, 20250001960682-25-000001EDGAR
- Form 1-SASep 30, 20240001960682-24-000007EDGAR
- Form 1-A POSSep 19, 20240001960682-24-000006EDGAR
- Form 1-KApr 29, 20240001960682-24-000005EDGAR
- Form 253G2Mar 26, 20240001960682-24-000003EDGAR
- Form 1-U/AFeb 8, 20240001960682-24-000002EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.